AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 10th, 2023 • Spero Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Executive Employment Agreement (this “Agreement”) is made and entered into this 1st day of August, 2023 by and between Spero Therapeutics, Inc., a Delaware corporation (“Company”), and Satyavrat Shukla (“Executive”).
CONSULTING AGREEMENTConsulting Agreement • August 10th, 2023 • Spero Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (the “Agreement”) is made effective as of July 15, 2023 (the “Effective Date”), by and between Spero Therapeutics, Inc., a Delaware corporation, with its principal place of business being 675 Massachusetts Ave, Cambridge, MA 02139 (the
CONSULTING AGREEMENTConsulting Agreement • August 10th, 2023 • Spero Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (the “Agreement”) is dated June 13, 2023, and is effective as of August 1, 2023, (the “Effective Date”) by and between Spero Therapeutics, Inc., with offices located at 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 02139, together with its subsidiaries and affiliates (collectively, “Spero”) and Ankit Mahadevia (“Consultant”). Spero and Consultant shall be referred to individually as a “Party” and together as the “Parties”.
TRANSITION AND SEPARATION AGREEMENTSeparation and Transition Agreement • August 10th, 2023 • Spero Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Separation and Transition Agreement (the “Agreement”) is made and entered into this 13th day of June, 2023 (the “Execution Date”) by and between Spero Therapeutics, Inc., a Delaware corporation (“Company”), and Ankit Mahadevia (“Executive”).
